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Abstract: New prognostic markers in patients with colorectal cancer (CRC) are a 
prerequisite for individualized treatment. Prognostic importance of single nucleotide 
polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene has 
been proposed. The objective of the present study was to investigate the prognostic 
importance of haplotypes in the VEGF-A gene in patients with CRC. The study included 
486 patients surgically resected for stage II and III CRC, divided into two independent 
cohorts. Three SNPs in the VEGF-A gene were analyzed by polymerase chain reaction. 
Haplotypes were estimated using the PHASE program. The prognostic influence was 
evaluated using Kaplan-Meir plots and log rank tests. Cox regression method was used to 
analyze the independent prognostic importance of different markers. All three SNPs were 
significantly related to survival. A haplotype combination, responsible for this effect, was 
present in approximately 30% of the patients and demonstrated a significant relationship 
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with poor survival, and it remained an independent prognostic marker after multivariate 
analysis, hazard ratio 2.46 (95% confidence interval 1.49–4.06), p < 0.001. Validation was 
provided by consistent findings in a second and independent cohort. Haplotype 
combinations call for further investigation. 
Keywords: colorectal neoplasm; single nucleotide polymorphisms; haplotypes; vascular 
endothelial growth factor A; survival 
 
1. Introduction 
Reliable prognostic markers are of great clinical importance in colorectal cancer (CRC). Several 
prognostic markers are already being used by clinicians to select patients for further postoperative 
treatment and adjuvant chemotherapy is standard of care for patients with high risk stage II and stage 
III CRC [1–5]. Nevertheless, tumor recurrence still occurs in patients with low risk stage II tumors and 
far from all patients receiving adjuvant chemotherapy benefit from their treatment. The identification 
of new prognostic markers in CRC is therefore a prerequisite for selection for adjuvant treatment in 
this patient category. 
Angiogenesis, the development of new blood vessels from the pre-existing vasculature, is a normal 
physiologic phenomenon but it also represents one of the classical hallmarks in the malignant 
transformation of tumors [6]. The vascular endothelial growth factor (VEGF) system is one of the most 
essential growth factor systems involved in neoangiogenesis in malignant tumors [7]. It influences the 
vasculature and affects the growth of tumors [8], and it provides a potential route for the dissemination 
of tumor cells and thereby increases the risk of metastatic spread [9]. The biologic availability of 
VEGF-A, the most important ligand in the VEGF system, therefore has the potential to influence the 
prognosis of patients with malignant diseases. 
The level of VEGF-A can, among other factors, be affected by normal sequence variations in the 
VEGF-A gene. Several of such normal variations, single nucleotide polymorphisms (SNPs), in the 
VEGF-A gene have been described. The −2578 C/A SNP (rs699947) and the −460 C/T SNP 
(rs833061) in the promoter region and the 405 G/C (rs2010963) in the 5’ untranslated region (5’UTR) 
are all very common and they are often analyzed in clinical studies. Associations between SNPs in the 
VEGF-A gene and the promoter activity of the gene and protein concentrations of VEGF-A have been 
demonstrated in some studies [10,11] and clinical studies have also suggested association with clinical 
outcome in breast [12], renal cell [13], gastric [14], colorectal [15–17], and ovarian cancer [18]. A high 
degree of linkage disequilibrium exists between several of the SNPs in the promoter and 5’UTR of the 
VEGF-A gene. It is therefore possible that a haplotype effect, rather than an individual effect of SNPs, 
might explain some of the prognostic information related to the genetic variations in this region of the 
gene. In agreement with this, haplotype analyses have supplied further information on these genetic 
variations [12,14,15]. Focus, however, has so far been on individual haplotypes rather than haplotype 
combinations. The latter may be relevant to providing specific information on the prognosis for each 
individual patient [19]. 
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The literature on the prognostic importance of SNPs in the VEGF-A gene in patients with CRC is 
still rather sparse, with conflicting results [15,17], and validation studies are warranted. Furthermore, 
only very few studies have reported on the effect of haplotypes. The aim of the present study was to 
perform a comprehensive analysis of the possible prognostic importance of haplotypes in the VEGF-A 
gene in two independent cohorts of patients with stage II and III CRC.  
2. Results and Discussion 
2.1. Patient Characteristics 
Patient characteristics are presented in Table 1. The two cohorts were comparable. No significant 
differences were found comparing allele frequencies between the two cohorts, and all three SNPs were 
found to be in Hardy-Weinberg equilibrium (p > 0.05). 
Table 1. Patient characteristics. Test cohort (n = 191) and validation cohort (n = 295). 
 Test cohort Validation cohort 
Number (%) Number (%) 
Sex   
  Male 98 (51) 159 (54) 
  Female 93 (49) 136 (46) 
Age (years)   
  Mean (SD) 70.1 (11.6) 70.5 (11.2) 
  Range 31–97 33–92 
pT category   
  1–3 159 (83) 248 (84) 
  4 32 (17) 47 (16) 
pN category   
  0 99 (52) 163 (55) 
  1–2 92 (48) 132 (45) 
Stage   
  II 98 (51) 163 (55) 
  III 93 (49) 132 (45) 
Localization   
  Colon 121 (63) 197 (67) 
  Rectum 70 (37) 98 (33) 
Vascular invasion   
  Yes 11 (9) 35 (12) 
  No 111 (91) 249 (88) 
Neuronal invasion   
  Yes 11 (9) 31 (12) 
  No 109 (91) 236 (88) 
Peritoneal perforation   
  Yes 26 (14) 38 (13) 
  No 160 (86) 253 (87) 
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Table 1. Cont. 
Adjuvant chemotherapy   
  No 157 (82) 232 (81) 
  Yes 34 (18) 53 (19) 
    5-FU/Leucovorin or capecitabine 34 (100) 28 (53) 
    XELOX 0 (0) 25 (47) 
−2578 C/A SNP   
  CC 47 (25) 80 (27) 
  CA 85 (45) 147 (50) 
  AA 59 (31) 68 (23) 
−460 C/T SNP   
  CC 59 (31) 69 (23) 
  CT 85 (45) 146 (49) 
  TT 47 (25) 80 (27) 
405 G/C SNP   
  GG 95 (50) 128 (43) 
  GC 74 (39) 129 (44) 
  CC 22 (12) 38 (13) 
Sum of the percentages do not always equal 100 % due to rounding of data. 
Not all patients had complete patient characteristics available. 
The median disease free survival (DFS) was 6.4 years (95% CI, 4.6–8.8) and the median overall 
survival (OS) was 7.2 years (95% CI, 5.3–9.3) in the test cohort. The median DFS was 5.8 years (95% 
CI, 5.1–5.8) in the validation cohort. The median OS was not reached in the validation cohort but does 
exceed 7.0 years. One hundred and two patients from the test cohort and 67 patients from the 
validation cohort died. Follow-up ended December 15, 2009 and data are reported with a median 
observation time of 9.8 years (range, 3.1–10.9) in the test cohort and 3.4 years (range, 1.0–7.8) in the 
validation cohort. 
No significant associations were found between the genotypes of the three SNPs and patient 
characteristics, as listed in Table 1, in either of the cohorts (data not shown). Tumors with the T 
categories 1, 2 and 3 were grouped together due to the presence of very few T1 and T2 tumors.   
The standard prognostic markers, T and N category, stage, vascular invasion and peritoneal perforation 
were all significantly associated with survival in both cohorts (data not shown). 
2.2. The Prognostic Value of VEGF-A SNPs 
Table 2 shows the relationship between SNP status and survival. The striking finding here is that 
the heterozygous VEGF-A genotypes (−2578 CA, −460 CT, and 405 GC) were all related to inferior 
survival rates compared to the corresponding homozygous genotypes in the test cohort. A comparison 
of the heterozygous genotypes to both homozygous genotypes was consequently performed although 
such a comparison differs from the conventional way of dividing genotypes. This strategy was kept in 
the following analyses in the validation cohort. The −460 C/T SNP were significantly related to DFS 
and OS in both cohorts.  
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Table 2. Relationship between SNP status and survival in both cohorts. All patients are included. 
Disease free survival (DFS) 
Test cohort  Validation cohort 
VEGF-A SNP and 
genotype comparison* 
Events HR (95% CI) p-value  VEGF-A SNP and 
genotype comparison* 
Events HR (95% CI) p-value 
−2578 C/A     −2578 C/A    
  CC (NR) v CA (3.3) 19 v 55 0.47 (0.30–0.75) <0.01    CC (5.6) v CA (5.8) 17 v 49 0.62 (0.37–1.03) 0.09 
  CC (NR) v AA (8.5) 19 v 29 0.83 (0.47–1.46) 0.52    CC (5.6) v AA (NR) 17 v 15 1.13 (0.57–2.26) 0.73 
  CA (3.3) v AA (8.5) 55 v 29 1.78 (1.16–2.74) 0.01    CA (5.8) v AA (NR) 49 v 15 1.75 (1.05–2.93) >0.05 
  CA v CC + AA  1.93 (1.29–2.89) <0.01    CA v CC + AA  1.68 (1.09–2.60) 0.02 
−460 C/T     −460 C/T    
  CC (8.5) v CT (3.3) 29 v 55 0.56 (0.37–0.86) 0.01    CC (NR) v CT (5.8) 15 v 50 0.55 (0.33–0.91) 0.04 
  CC (8.5) v TT (NR) 29 v 19 1.21 (0.68–2.14) 0.52    CC (NR) v TT (5.6) 15 v 16 0.91 (0.45–1.85) 0.80 
  CT (3.3) v TT (NR) 55 v 19 2.11 (1.33–3.35) <0.01    CT (5.8) v TT (5.6) 50 v 16 1.73 (1.05–2.87) >0.05 
  CT v CC + TT  1.93 (1.29–2.89) <0.01    CT v CC + TT  1.78 (1.15–2.75) 0.01 
 405 G/C      405 G/C    
  GG (7.5) v GC (4.3) 50 v 43 0.73 (0.48–1.11) 0.13    GG (NR) v GC (5.0) 24 v 48 0.41 (0.26–0.65) <0.01 
  GG (7.5) v CC (NR) 50 v 10 1.16 (0.61–2.22) 0.67    GG (NR) v CC (NR) 24 v 9 0.69 (0.30–1.60) 0.34 
  GC (4.3) v CC (NR) 43 v 10 1.55 (0.84–2.85) 0.21    GC (5.0) v CC (NR) 48 v 9 1.66 (0.90–3.06) 0.16 
  GC v GG + CC  1.40 (0.93–2.12) 0.09    GC v GG + CC  2.22 (1.42–3.46) <0.01 
Overall survival (OS) 
Test cohort  Validation cohort 
VEGF-A SNP and 
genotype comparison* 
Events HR (95% CI) p-value  VEGF-A SNP and 
genotype comparison* 
Events HR (95% CI) p-value 
−2578 C/A     −2578 C/A    
  CC (NR) v CA (4.7) 18 v 55 0.46 (0.29–0.74) <0.01    CC (6.1) v CA (NR) 12 v 40 0.55 (0.31–0.97) 0.06 
  CC (NR) v AA (8.8) 18 v 29 0.79 (0.44–1.40) 0.42    CC (6.1) v AA (7.0) 12 v 15 0.84 (0.39–1.79) 0.65 
  CA (4.7) v AA (8.8) 55 v 29 1.71 (1.12–2.63) 0.02    CA (NR) v AA (7.0) 40 v 15 1.38 (0.79–2.41) 0.28 
  CA v CC + AA  1.89 (1.27–2.82) <0.01    CA v CC v AA  1.57 (0.97–2.54) 0.07 
−460 C/T     −460 C/T    
  CC (8.8) v CT (4.7) 29 v 55 0.58 (0.38–0.90) 0.02    CC (7.0) v CT (NR) 15 v 41 0.69 (0.40–1.20) 0.22 
  CC (8.8) v TT (NR) 29 v 18 1.27 (0.72–2.26) 0.42    CC (7.0) v TT (NR) 15 v 11 1.26 (0.58–2.72) 0.56 
  CT (4.7) v TT (NR) 55 v 18 2.15 (1.35–3.43) <0.01    CT (NR) v TT (NR) 41 v 11 1.99 (1.13–3.53) 0.04 
  CT v CC + TT  1.89 (1.27–2.82) <0.01    CT v CC + TT  1.66 (1.03–2.68) 0.04 
 405 G/C      405 G/C    
  GG (8.3) v GC (4.8) 50 v 43 0.72 (0.47–1.10) 0.11    GG (NR) v GC (5.8) 23 v 39 0.51 (0.31–0.84) 0.01 
  GG (8.3) v CC (NR) 50 v 9 1.33 (0.70–2.54) 0.43    GG (NR) v CC (NR) 23 v 5 1.21 (0.49–3.02) 0.70 
  GC (4.8) v CC (NR) 43 v 9 1.82 (0.99–3.35) 0.10    GC (5.8) v CC (NR) 39 v 5 2.25 (1.11–4.58) 0.08 
  GC v GG + CC  1.46 (0.97–2.20) 0.06    GC v GG + CC  2.00 (1.23–3.25) <0.01 
* Median DFS and OS in years are given in parentheses. CI: confidence interval; NR: not reached. 
The poor survival related to the heterozygous genotypes in the univariate analyses was also seen in 
the multivariate analyses. This is presented in Table 3, which shows the results of the multivariate 
survival analysis from the validation cohort. The possible independent prognostic value of each SNP 
was assessed here individually. The table therefore summarizes the results from three separate Cox 
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regression models all including T category, N category, vascular invasion, neuronal invasion, 
peritoneal perforation and adjuvant treatment. The −2578 C/A and the 405 G/C SNPs both 
demonstrated prognostic value independent of the standard prognostic markers regarding DFS. A 
possible independent value, although not significant, was seen for the −460 C/T SNP. A similar 
multivariate survival analysis adjusted for the same variables was initially performed on the test 
cohort, with similar findings although the 405 G/C SNP failed to demonstrate an independent 
prognostic value (data not shown). 
Table 3. Multivariate survival analysis according to the VEGF-A SNPs. Validation cohort, n = 295. 
Genotypes 
Disease free survival (DFS) Overall survival (OS) 
HR (95% CI) p-value HR (95% CI) p-value 
−2578 C/A     
  CC 1  1  
  CA 1.98 (1.10–3.56) 0.02 1.92 (0.98–3.76) 0.06 
  AA 1.10 (0.53–2.28) 0.80 1.32 (0.60–2.92) 0.49 
−460 C/T     
  CC 1  1  
  CT 1.81 (0.99–3.31) 0.06 1.46 (0.79–2.72) 0.23 
  TT 0.89 (0.42–1.87) 0.76 0.73 (0.32–1.64) 0.44 
405 G/C     
  GG 1  1  
  GC 1.79 (1.06–3.01) 0.03 1.52 (0.88–2.63) 0.13 
  CC 0.98 (0.43–2.26) 0.97 0.73 (0.27–1.98) 0.53 
The VEGF-A SNPs were added individually to the multivariate analysis and the hazard ratios therefore 
represent the results from three separate Cox regression models all including T category, N category, 
vascular invasion, neuronal invasion, peritoneal perforation and adjuvant treatment. HR: hazard ratio;  
CI: confidence interval. 
2.3. Haplotype Analysis 
The haplotype analysis was performed to evaluate a possible combined effect of the SNPs  
(−2578 C/A, −460 C/T, 405 G/C) on CRC survival. Three haplotypes with a frequency above 0.5%, 
(ACG, 52.3%; CTC, 31.3%; CTG, 16.4%) in the test cohort and (ACG, 47.8%; CTC, 34.7%;  
CTG, 17.0%) in the validation cohort, were defined by the PHASE program based on population 
frequencies of the three SNPs. This meant that each patient could be identified by one of six possible 
haplotype combinations due to our bi-allelic nature.  
The initial analyses in the test cohort revealed a combination (CTC, ACG) present in 29% of the 
patients, related to inferior survival rates and differing significantly from four of the remaining five 
combinations. The survival rates for these four combinations, constituting 55% of the patients, were 
very similar and did not differ significantly from each other. The patients with the last combination 
(CTG, ACG) presented with an intermediate prognosis not differing significantly from any of the other 
combinations. This is illustrated graphically in Figure 1 showing the OS curves from the test cohort 
according to the haplotype combinations. Similar DFS curves were seen (data not shown) and it 
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therefore seemed reasonable to pool the patients with haplotype combinations different from the (CTC, 
ACG) and (CTG, ACG) combinations in one group for the following analyses in the validation cohort.  
Figure 1. Kaplan-Meier overall survival curves according to haplotype combinations. The 
blue line represents patients with the (CTC, ACG) haplotype combination and the yellow 
line patients with the (CTG, ACG) combination. Patients with the remaining four 
haplotype combinations are represented by the grey lines, test cohort, n = 191. 
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Figure 2 shows the significant differences in DFS and OS seen in both cohorts based on the above 
considerations. The results from the validation cohort confirmed the inferior survival rates seen in the 
test cohort for the patients with the (CTC, ACG) combination and furthermore the favorable survival 
rates seen for the combined group. The median DFS for the patients with the (CTC, ACG) 
combination was 2.6 years (95% CI, 2.0–4.4) in the test cohort compared to 3.2 years (95% CI,  
2.2–5.8) in the validation cohort. The patients from the combined group presented with a median DFS 
of 9.5 years (95% CI, 6.5–9.5) in the test cohort. The median DFS for this group was not reached in 
the validation cohort but exceeds 5.5 years. The results from the validation cohort could not confirm 
the intermediate prognosis for the patients with the (CTG, ACG) combination who presented with 
survival rates similar to the survival rates seen for the combined group and consequently, only the 
(CTC, ACG) combination seems to be related to poor survival. 
Table 4 shows the results of the multivariate survival analysis according to the haplotype 
combinations, and involves the same patient characteristics as in Table 3. The (CTC, ACG) haplotype 
combination remained an independent prognostic marker in both cohorts with hazard ratios ranging 
from 2.04 to 2.46, respectively.  
We also performed subgroup analyses running separate survival analyses for patients with colon 
and rectal cancers and for patients with stage II and III disease. These results did not indicate that the 
present findings were more pronounced in either of the groups (data not shown). 
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Figure 2. A to D Kaplan-Meier survival curves according to haplotype combinations. The 
blue line represents patients with the (CTC, ACG) haplotype combination and the yellow 
line patients with the (CTG, ACG) combination. Patients with the remaining four 
haplotype combinations are represented by a single grey line. All patients from both 
cohorts are included. 
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Table 4. Multivariate survival analysis according to haplotype combinations in both 
cohorts. All patients are included. 
Disease free survival (DFS) 
Test cohort  Validation cohort 
 HR (95% CI) p-value   HR (95% CI) p-value 
Remaining combinations 1   Remaining combinations 1  
(CTG, ACG) 1.85 (0.95–3.62) 0.07  (CTG, ACG) 0.98 (0.44–2.18) 0.97 
(CTC, ACG) 2.04 (1.14–3.67) 0.02  (CTC, ACG) 2.46 (1.49–4.06) <0.01 
Overall survival (OS) 
Test cohort  Validation cohort 
 HR (95% CI) p-value   HR (95% CI) p-value 
Remaining combinations 1   Remaining combinations 1  
(CTG, ACG) 1.72 (0.89–3.36) 0.11  (CTG, ACG) 0.95 (0.40–2.21) 0.90 
(CTC, ACG) 2.15 (1.21–3.82) 0.01  (CTC, ACG) 2.07 (1.20–3.57) 0.01 
The Cox regression models all included T category, N category, vascular invasion, neuronal invasion, 
peritoneal perforation and adjuvant treatment, HR; hazard ratio, CI; confidence interval. 
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2.4. Discussion 
New prognostic markers are a prerequisite for selecting patients with CRC for adjuvant treatment. 
A number of recent publications have suggested that SNPs in the VEGF-A gene are biomarkers of 
prognostic importance in different types of malignant tumors including CRC [15–17]. However, the 
results of these studies are contradictory, probably because of varying patient materials, and the role of 
haplotypes needs to be elucidated. Therefore, the aim of this study was to analyze the prognostic 
influence of haplotypes in the VEGF-A gene in patients with stage II or III CRC based on a test and a 
validation cohort. 
The three SNPs in the present study were chosen, as they are very common and because previous 
studies have reported on functional as well as prognostic influences [10–18]. Furthermore, they are all 
located in rather close proximity in a region of the gene in which a high degree of linkage 
disequilibrium exists and haplotype effects might therefore be a possibility. The genotype frequencies 
of these SNPs in our study are in rather good agreement with those reported in the literature on CRC 
patients [15,20–22].  
The −2578 C/A, the −460 C/T and the 405 G/C SNPs all showed a significant relationship with 
survival, and in all three cases the heterozygous genotypes were related to poor survival. We know that 
comparing heterozygous versus both homozygous is not the conventional way of grouping genotypes 
but the present results called for this unconventional approach. Multivariate analysis of DFS 
(performed with each SNP individually) confirmed a significant prognostic value related to the  
−2578 C/A and 405 G/C SNPs independent of standard prognostic markers. Kim et al. examined the 
prognostic influence of VEGF-A SNPs in 445 Korean patients operated for CRC stage I to IV [15]. 
The results suggested that compared to the other genotypes the VEGF-A 405 GG genotype was 
associated with inferior survival rates. The −2578 C/A SNP did not show any relationship with 
survival. A second study, by Dassoulas et al. reported that the VEGF-A −2578 AA and 405 CC 
genotypes were related to significantly lower OS in 312 Greek patients operated for CRC stage I to IV. 
The influence by the −460 C/T SNP did not reach statistical significance [17]. The results from our 
study, the Greek, and the Korean studies, clearly demonstrate the diversity between studies dealing 
with the prognostic importance of SNPs. First of all, any difference in the allelic frequencies and the 
phenotypic outcome, survival, would make it difficult to compare the prognostic value of genetic 
markers between ethnically different groups. Furthermore, differences in the disease stages included in 
the studies might also explain some of the discrepancies. Stage is a very strong prognostic parameter, 
and the fraction of patients with stage I and IV disease differed a great deal between the Greek and 
Korean studies. We only included patients with stage II and III disease because this is the group of 
patients in which new prognostic markers are most warranted.   
As expected, we observed rather similar results for all three SNPs presumably due to the high 
degree of linkage disequilibrium known to exist in this region of the gene. The link between the  
−2578 C/A and the −460 C/T SNPs actually turned out to be stronger than initially expected. The 
distribution of genotypes was identical in the test cohort and only differed in a small number of 
patients in the validation cohort. Therefore, it can not be ruled out that an underlying haplotype effect 
can explain some of the apparent prognostic power associated with the genetic variations in this region 
of the gene.  
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The haplotype frequencies from the present study were in a rather good agreement with the 
haplotype frequencies reported in the literature [15,17,22,23]. Any differences could very well be 
explained by ethnical differences, but also the source of DNA could account for some of the 
differences. The Korean studies are based on tumor DNA, where the presence of loss of heterozygosity 
(LOH) would lead to changes in the observed frequencies of the haplotypes. 
The present haplotype analysis identified three frequent haplotypes and all patients could 
consequently be identified by one of six haplotype combinations. The haplotype analysis demonstrated 
a significant relationship between poor survival rates and patients with the (CTC, ACG) combination 
compared to survival rates for the remaining patients. A group of patients (CTG, ACG) with a 
presumable intermediate prognosis was identified in the test cohort, but this was not confirmed by the 
following analysis in the validation cohort suggesting that patients with haplotype combinations 
different from (CTC, ACG) have a somewhat similar prognosis. The (CTC, ACG) combination also 
remained an independent prognostic marker after the multivariate survival analysis in both cohorts. 
The two haplotypes, CTC and ACG, might be linked to two independent genetic variations, both 
being of prognostic importance for different reasons and both acting in a dominant fashion. This would 
explain the inferior survival rates demonstrated for patients harboring both haplotypes compared to 
patients with only one of the haplotypes on one or both alleles. It should be pointed out that the 
associations to heterozygosity for −2578 C/A, −460 C/T and 405 G/C demonstrated in Tables 2 and 3 
are easily explained by the fact that the haplotype combination (CTC, ACG) will result in 
heterozygosity for these three SNPs. These genetic variations may lead to a differential influence on 
the tumor vasculature and thereby the risk of dissemination of tumor cells in the individual patients 
ultimately resulting in a difference in prognosis.   
The Korean study by Kim et al. [15] found the −2578 A, 405 G, 936 T haplotype to be associated 
with inferior survival rates. The Greek study by Dassoulas et al. [17] assessed the clinical importance 
of haplotypes based on the −2578 C/A, 405 G/C and 936 C/T SNPs but found no associations with 
survival or clinicopathological characteristics. Given the strong linkage between the −2578 C/A and 
the −460 C/T SNPs, the haplotype associated with inferior survival rates in the Korean study probably 
represent the ACG haplotypes from the present study. So despite rather large differences between our 
results on genotype level, some agreement seems to exist on the haplotype level. 
Using genomic DNA derived from blood holds several technical as well as biological advantages 
compared to tumor DNA. Genomic DNA is easy to assess through a blood test compared to more 
invasive procedures such as biopsies. It is constant over time and not influenced by tumor biology or 
treatment. The quality of blood derived DNA is often higher than the tissue derived DNA thereby 
improving the quality of the analyses and the time spent on optimizing procedures. 
The retrospective design of the present study has its limitations, but our conclusions are 
strengthened by the validation performed on an independent cohort. The study presented here with 
focus on CRC stages II and III is the largest one in the field so far but the sample size is still too small 
to draw any definite conclusions and prospective validation is still warranted to provide further evidence.  
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3. Experimental Section 
3.1. Study Population 
This retrospective study on 486 patients, all Caucasians, consisted of a test cohort of 191 patients 
operated between January 1999 and December 2000 and a validation cohort of 295 patients operated 
between January 2002 and December 2008. Besides being operated at different time periods, the two 
cohorts also differed with regard to the patient materials available for analyses, formalin fixated 
paraffin embedded (FFPE) tissue in the test cohort and blood samples in the validation cohort. All 
patients underwent surgical resection of histologically verified adenocarcinomas of the colon or 
rectum at the Department of Surgery, Vejle Hospital, Denmark. The study only included patients with 
stage II and III disease. Patients having received preoperative chemoradiation of rectal cancer were not 
included. Furthermore, patients who died of post-operative complications or within one month from 
the operation were excluded (16 patients from the test cohort and 14 patients from the validation 
cohort). All patients from the two cohorts meeting these inclusion criteria were included in the study 
and hence no specific power calculations were applied to determine the sample size. Pre-treatment 
examinations included a chest X-ray and ultrasound or CT scan of the abdomen. Postoperatively the 
tumors were histologically classified and staged according to the pTNM system. Information regarding 
patient characteristics, relapse status and survival were based on patient records and registries. The 
study was approved by the Regional Scientific Ethical Committee for Southern Denmark according to 
Danish law, and informed consent was obtained from all patients enrolled in the study.  
3.2. Analysis of Single Nucleotide Polymorphism 
Genomic DNA from the test cohort was derived from FFPE tissue. Fifty-μm sections of FFPE 
normal colorectal tissue were initially treated with xylene for deparaffinization and then washed two 
times in ethanol (99%). Samples were then incubated for two days in a lysis buffer and proteinase K at 
56 °C. Genomic DNA from the validation cohort was derived from whole blood, which was obtained 
at the operation and stored at −20 °C. The DNA from both cohorts was isolated using the 
NucleoSpin® Tissue method according to the user manual (Machery-Nagel, Düren, Germany,) 
(http://www.mn-net.com/Portals/8/attachments/Redakteure_Bio/Protocols/Genomic%20DNA/UM_g 
DNATissue.pdf) and by the Maxwell® method (after 2006) according to the user manual (Promega 
Corporation, WI, USA) (http://www.promega.com/tbs/tm284/tm284.pdf). 
The PCR analysis was performed using the ABI PRISM 7900 HT fast real-time PCR system 
(Applied Biosystem, Foster City, CA, U.S.A.). Commercial assays (which were functionally tested or 
validated from Applied Biosystem) were used for the analysis of the VEGF-A SNPs. Assay numbers 
and the approximate length of the amplification products (estimated by gel electrophoresis) were as 
follows: The VEGF-A −2578 C/A SNP; rs699947; C___8311602_10; 110/90 base pairs (depending on 
genotypes), the VEGF-A −460 C/T SNP; rs833061; C___1647381_10; 120 base pairs and the  
VEGF-A 405 G/C SNP; rs2010963; C___8311614_10; 100 base pairs. 
In each well, of a 96 well microtiter plate, 10 μL were added consisting of 2 μL DNA and 8 μL of a 
mastermix containing the two primers and probes from the assay and universal PCR mix (also Applied 
Biosystems). Controls were analyzed along with the samples for final identification of the genotypes. 
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The PCR analysis was conducted according to standard procedures with cycling conditions initially at 
50 °C for 2 min and 95 °C for 10 min. This was followed by 40 cycles at 95 °C for 15 s (for 
denaturation), and 60 °C for 1 min (for annealing and elongation). Following end-point reading, 
genotypes were visualised on an allelic discrimination plot. Samples, from which the test results did 
not meet the quality value threshold, 95% for DNA derived from the blood samples and 98% for DNA 
derived from FFPE tissue, were diluted and reanalyzed. This was only necessary for a few samples. 
The SNP analysis was performed without knowledge of the clinical data. 
3.3. Statistical Analysis 
Fisher’s exact test was used for comparison between genotypes and patient characteristics.  
Chi-square statistics were used to test for Hardy-Weinberg equilibrium. The haplotypes and their 
frequencies were estimated using the PHASE program, version 2.1, which implements a Bayesian 
statistical method for reconstructing haplotypes from genotype data [24,25]. No patients had missing 
SNP data. Disease free survival was defined as the time from surgery until the first documented tumor 
recurrence or death. Overall survival was defined as the time from surgery until death. Survival curves 
were illustrated according to the Kaplan-Meier method and the logrank test was used to test for 
differences between the groups. Survival data from patients diagnosed with a new malignancy after 
their surgical resection for CRC (12 patients from the test cohort and nine from the validation cohort) 
were censored from the date of their new cancer diagnosis. This was done to prevent any possible bias 
related to the presence of a new cancer or the chemotherapeutic treatments used. Furthermore, survival 
data from seven patients were incomplete (five patients from the test cohort and two patients from the 
validation cohort) and were censored from the date of their last patient record. Cox regression method 
was used to analyze the independent prognostic importance of different markers. All statistical 
calculations were carried out using the NCSS statistical software (NCSS Statistical Software, Kaysville, 
UT 84037, USA, version 2007). P values <0.05 were considered significant, and all tests were two sided. 
4. Conclusions 
In conclusion, this validating study of nearly 500 patients from two independent cohorts with stage 
II and III CRC identified a genetic signature related to the prognosis of patients with stage II and III 
CRC based on genetic variations in the promoter and 5’UTR of the VEGF-A gene. Analysing 
haplotype combinations, we were able to identify a group with a rather favorable prognosis and a 
group in which adjuvant chemotherapy seems indicated. The possible benefit from such a treatment, 
however, cannot be assessed from the present results. This unfavorable haplotype combination 
remained an independent prognostic marker. Future studies should focus more on haplotype analyses 
because of higher degrees of consistency between studies. The haplotype combination approach calls 
for further investigation.  
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